[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
Indexing Databases::
Editorial Board::
Executive Members::
Instruction to Authors::
Peer Review::
Articles Archive::
Contact Us::
Site Facilities::
::
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
:: Search published articles ::
Showing 1 results for Masoudzadeh

Abbas Masoudzadeh, , ,
Volume 9, Issue 4 (12-2007)
Abstract

Background & Objective: In spit of high prevalancey of the Obsessive-Compulsive Disorder in anxity diseases. It shows the least therapeutic responses. This study was done to determine The comparison of therapeutic effect of Naltrexone and Flouxetine on Obsessive-Compulsive Disorder (O.C.D).

Materials & Methods: This double-blind clinical trial study was done on 30 patients aged 18 to 60 years referring to the clinics of psychiatry at Zareh hospital in Sari-Iran during 2006. Patients in three groups, treated with flouxetine 53.9mg/d (group A) Naltrexone 64.4mg/d (groupe B) & Pelacebo (group C) in the same shape capsula respectively. The severity of O.C.D was evaluated at 4 steps with Yale-Brown scale.the obtained data were analyzed using parametric & nonparametric tests.

Results: Naltrexone reduced the severity of O.C.D symptoms significantly (45.01%) at the end of week 8th (p<0.05). Same result (45.81%) was observed using Flouxetine (P=0.79). The rate of efficaey in both drugs significantly was higher than pelacebo (P<0.05).

Conclusion: This study showed thant, Naltrexone has the same level of reducting symptome of OCD but even with faster therapeutic effect than Flouxetin.



Page 1 from 1     

مجله دانشگاه علوم پزشکی گرگان Journal of Gorgan University of Medical Sciences
Persian site map - English site map - Created in 0.1 seconds with 23 queries by YEKTAWEB 4714
Creative Commons License
This work is licensed under a Creative Commons — Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)